COVID-19 Impact on Inovio Pharmaceuticals Inc.
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio’s focus is on DNA-based vaccines requiring a novel route of administration
Inovio’s pipeline is most active in early-stage drug development
INO-4800 is Inovio’s COVID-19 vaccine
Funding from different sources for INO-4800
Scope
This 29-page PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Reasons to Buy
An overview of how Inovio Pharmaceuticals Inc. will be affected by the COVID-19 pandemic.
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Pharmaceuticals reports

